Overview

Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders

Status:
ENROLLING_BY_INVITATION

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

Results of the application of 100 sessions of tDCS for 12 months in children between 6 and 11 years old with autism spectrum disorder with rare diseases, genetic problems or PANDAS

Phase:

PHASE1

Details

Lead Sponsor:

Spanish Foundation for Neurometrics Development

Collaborator:

Fundacion para la Salud Materno Infantil

Treatments:

Diet
Risperidone
Speech Therapy
Transcranial Direct Current Stimulation